StemCells Inc. (STEM) PT Lowered to $1.15 at S&P Equity Research
StemCells Inc. (NASDAQ:STEM) had its price objective dropped by equities research analysts at S&P Equity Research from $1.36 to $1.15 in a report issued on Friday. S&P Equity Research’s price target suggests a potential upside of 3.60% from the stock’s previous close.
StemCells (NASDAQ:STEM) traded up 18.02% during trading on Friday, reaching $1.31. The company’s stock had a trading volume of 4,035,074 shares. The company’s market cap is $15.73 million. StemCells has a 52-week low of $0.33 and a 52-week high of $6.96. The stock has a 50-day moving average price of $1.01 and a 200 day moving average price of $1.18.
Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. raised its stake in StemCells by 94.2% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 453,823 shares of the company’s stock worth $617,000 after buying an additional 220,150 shares during the last quarter. D. E. Shaw & Co. Inc. bought a new stake in StemCells during the third quarter worth about $362,000. Finally, KCG Holdings Inc. raised its stake in StemCells by 83.1% in the third quarter. KCG Holdings Inc. now owns 137,489 shares of the company’s stock worth $187,000 after buying an additional 62,394 shares during the last quarter. Institutional investors own 5.71% of the company’s stock.
StemCells, Inc (StemCells) is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. Its lead product development program is its central nervous system (CNS) program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology.
Receive News & Stock Ratings for StemCells Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemCells Inc. and related stocks with our FREE daily email newsletter.